In our proof-of-concept study to demonstrate the potential of controlling Th17 cells by targeting TGF-β signalling, we included as positive control anti-IL17 treatment, since the arthritis model we used is known to be dependent on CD4 + T cells and IL-1720,53. This evidence concerns the gene IL17A and arthritic joint disease.